← All candidates
Two insider buys in the last year — $44.0K in all.
12 filings on record.
CNSPCNS Pharmaceuticals, Inc.
NasdaqCM · Healthcare · $8.33M
$5.70
+0.00% · Sep 15
Two insider buys in the last year — $44.0K in all.
Nothing in the last fortnight.
Price · 1Y · daily● 2 buys◆ 3 8-K
▸ hover a marker for the filing · drag to zoom · 4 moves explained
Reverse-split 4×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what CNSP ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$8.33M
Float
1.3M
90% public
Short % float
Pro
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Director
Charles Faith L.
Bought $34.0K on May 18 — 7,100 sh @ $4.79, held direct, 100% of their stake.
No completed positions to measure
Director
Fisher Michal
Bought $10.0K on May 18 — 2,000 sh @ $5.00, held direct, 100% of their stake.
First Form 4 on file
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
1 filingnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
Context
Wall St
$10.00 avg target
+75.4% vs today · 1 analyst
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
The file stays open
12 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice